Clinical trials: Omeprazole
Reflux Esophagitis (RE)
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
- Trial name
- NCT06850480
- Testing
- JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Healthy Volunteers, Pharmacologic Action
Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole
Midazolam is a rapid-acting benzodiazepine, with a short half-life (approximately 1.9 hours) and is primarily metabolised by CYP3A. Omeprazole is a selective proton pump inhibitor substrate used to reduce gastric acid secretion.
- Trial name
- NCT02190708
- Testing
- PQ912, Midazolam, Omeprazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vivoryon Therapeutics N.V.
Healthy
YH4808 Postprandial PK/PD Study in Healthy Subjects
A clinical Study to evaluate the safety and pharmacokinetics/pharmacodynamics(PK/PD) of YH4808 after repeated Oral administration and Postprandial state in healthy volunteers
- Trial name
- NCT01761513
- Testing
- YH4808
- Where
- South Korea
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
This is a multi-center, open-label, phase I study to assess the effects of dovitinib (TKI258) on the pharmacokinetics of a cocktail of caffeine, diclofenac, omeprazole and midazolam in patients with advanced solid tumors…
- Trial name
- NCT01596647
- Testing
- caffeine, diclofenac, omeprazole
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
NSAID Induced Gastropathy
Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy
Primary objective: To determine the levels of malondialdehyde (MDA) and immunohistochemistry surrogate of inflammation in patients with NSAID-induced gastric mucosal injury treated with Rebamipide 3x a day vs Esomeprazole 40mg…
- Trial name
- NCT00641004
- Testing
- Rebamipide and Esomeprazole
- Where
- 4 sites in Philippines
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Neoplasms, Breast
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.
- Trial name
- NCT00849329
- Testing
- lapatinib, lapatinib plus esomeprazole
- Where
- 4 sites in United States, South Korea and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Healthy
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to…
- Trial name
- NCT00206050
- Testing
- Esomeprazole, pantoprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in healthy adult participants.
- Trial name
- NCT05109390
- Testing
- Danicopan, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Atopic Dermatitis
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: 14 weeks of treatment with tralokinumab a single dose of tralokinumab
- Trial name
- NCT03556592
- Testing
- Tralokinumab, Caffeine, Warfarin
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Weight Management
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2…
- Trial name
- NCT06562907
- Testing
- GS-4571, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Healthy Subjects
A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021
Part A: a single-center, randomized, open-label, three-cycle study to evaluate the pharmacokinetic (PK) profile of different doses of ABSK021 Capsules and the effect of a high-fat meal on the pharmacokinetic profile of ABSK021…
- Trial name
- NCT06322706
- Testing
- ABSK021, Omeprazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Abbisko Therapeutics Co, Ltd
Gastroesophageal Reflux Disease
Esomeprazole in PPI Failures - IMPROVE
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation…
- Trial name
- NCT00272701
- Testing
- Esomeprazole, Other PPI marketed in Sweden
- Where
- 42 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Healthy
Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers
The objective of this trial was to quantify the effect of oral single-dose (480 mg) and steady-state BI 201335 NA (240 mg BID) on intestinal and hepatic cytochrome P450 (CYP) and P-glycoprotein (P-gp) probe drugs as a means of…
- Trial name
- NCT02182336
- Testing
- BI 201335 NA, Caffeine, Warfarin sodium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
The main objective of this trial is to investigate: the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs.
- Trial name
- NCT06193811
- Testing
- Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05891119
- Testing
- Caffeine, Metoprolol, Midazolam
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Amgen
Normal Healthy Subject Population
Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.
- Trial name
- NCT00808769
- Testing
- Zegerid®, Prilosec OTC®
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Healthy
A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood
The main objective of this trial is to investigate the effect of the proton pump inhibitor esomeprazole on the pharmacokinetics of BI 1819479 in plasma.
- Trial name
- NCT05467475
- Testing
- BI 1819479, Esomeprazole
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca